A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis Meeting Abstract
| Authors: | Hagen, P.; Sidana, S.; Parker, T. L.; Walker, B. K.; Hoering, A.; Sanchorawala, V.; Zonder, J. A.; Kourelis, T.; D'Souza, A.; Landau, H. J.; Rosenthal, A.; Ailawadhi, S.; Orlowski, R. Z. |
| Abstract Title: | A phase III, randomized study of daratumumab, cyclophosphamide, bortezomib and dexamethasone (DARA-VCD) induction followed by autologous stem cell transplant or DARA-VCD consolidation and daratumumab maintenance in patients with newly diagnosed AL amyloidosis |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557406352 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.TPS7575 |
| Notes: | Meeting Abstract: TPS7575 -- Source: Wos |
